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Abstract
Erythropoietin (Epo) is used for managing anemia in
cancer patients. However, recent studies have raised
concerns for this practice. We investigated the ex-
pression and function of Epo and the erythropoietin
receptor (EpoR) in tumor biopsies and cell lines from
human head and neck cancer. Epo responsiveness of
the cell lines was assessed by Epoetin-A–induced
tyrosine phosphorylation of the Janus kinase 2 (JAK2)
protein kinase. Transmigration assays across Matri-
gel-coated filters were used to examine the effects of
Epoetin-A on cell invasiveness. In 32 biopsies, we
observed a significant association between disease
progression and expression of Epo and its receptor,
EpoR. Expression was highest in malignant cells,
particularly within hypoxic and infiltrating tumor
regions. Although both Epo and EpoR were expressed
in human head and neck carcinoma cell lines, only
EpoR was upregulated by hypoxia. Epoetin-A treat-
ment induced prominent JAK2 phosphorylation and
enhanced cell invasion. Inhibition of JAK2 phospho-
rylation reduced both basal and Epo-induced invasive-
ness. Our findings support a role for autocrine or
paracrine Epo signaling in the malignant progression
and local invasiveness of head and neck cancer. This
mechanism may also be activated by recombinant
Epo therapy and could potentially produce detrimental
effects in rhEpo-treated cancer patients.
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Introduction
Erythropoietin (Epo) treatment increases hematocrit and
improves fatigue in anemic cancer patients [1]. However,
recent studies have raised the possibility that rhEpo treat-
ment may also exert direct biologic actions on human
cancer cells [2–5]. Two recent clinical trials in fact sug-
gested possible clinical worsening associated with rhEpo
use [6,7]. One of these trials evaluated 351 head and neck
cancer patients and found poorer locoregional progression-free
survival in rhEpo-treated patients versus the placebo group [7].
The other trial, which enrolled 939 patients with metastatic
breast cancer, was terminated prematurely because of an
increased incidence of disease progression and a higher early
mortality in patients receiving rhEpo. [6]. Although the under-
lying mechanism for these findings remains unknown, these
studies raise the question of whether Epo can act on erythro-
poietin receptors (EpoRs) expressed by tumor cells to enhance
their malignant properties.
Expression of the Epo and EpoR genes in neoplastic lesions
has recently been documented and correlated with poor prog-
nosis in several human cancers including breast [8], cervical
[3], and endometrial carcinomas [9]. It is possible that some of
the newly appreciated, nonhematopoietic biologic activities of
Epo signaling, such as promotion of angiogenesis [10] and
inhibition of apoptosis [11], may contribute to disease progres-
sion in human cancers. We performed this study to determine
whether Epo signaling mechanisms were expressed by, and
had biologic effects in, head and neck cancer. We investigated
the expression of Epo and EpoR in human head and neck
cancer specimens and explored the biologic effects of Epo on
head and neck carcinoma cell lines. Our results are consistent
with a role for autocrine or paracrine Epo signaling in head and
neck squamous cell carcinoma (HNSCC) progression and
invasion. This mechanismmay contribute to adverse outcomes
associated with tumor hypoxia and with exogenous rhEpo
treatment of cancer patients.
Abbreviations: Epo, erythropoietin; rhEpo, recombinant human Epo; EpoR, erythropoietin
receptor; JAK2, Janus kinase 2; HIF-1, hypoxia-inducible factor 1; HNSCC, head and neck
squamous cell carcinoma
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Methods
Clinical Samples and Clinical Data
Study protocols involving human material were approved
by the University of Pennsylvania Institutional Review Board
(Philadelphia, PA). Thirty-two cases of HNSCC biopsies
or tumor resections (larynx—nine; aryepiglottic fold—five;
epiglottis—four; tongue—four; retromolar trigone—four;
cervical lymph node—six) were selected from the Surgical
Pathology files of the University of Pennsylvania Medical
Center. Hematoxylin and eosin (H&E)–stained slides of all
cases were reviewed and the diagnoses were confirmed.
Invasive carcinomas as well cases of carcinoma in situ were
also evaluated. All specimens were primary resection or
pretreatment biopsies from patients with no prior treatment
with Epo.
Immunohistochemistry and Immunocytochemistry
Immunohistochemical assays were performed on
formalin-fixed paraffin-embedded sections as described pre-
viously [3,8]. Five-micrometer–thick sections were cut and
deparaffinized in xylene and rehydrated in graded alcohols.
All slides were steamed in 0.01 M sodium citrate buffer
(pH 6.0) for 20 minutes. Endogenous peroxidase activity
was blocked by 3% hydrogen peroxide in methanol for
20 minutes. Slides were incubated with the antibodies
against Epo (rabbit polyclonal, H-162, 1:200 dilution; Santa
Cruz Biotechnologies, Santa Cruz, CA) and EpoR (rabbit
polyclonal, C-20, 1:400 dilution; Santa Cruz Biotechnologies)
overnight at 4jC. Slides were then washed five times with
Tris-buffered saline containing Tween 20 (TBST, pH 7.6;
DAKO, Carpinteria, CA) and incubated for 30 minutes at
room temperature with horseradish peroxidase– labeled
dextran polymer coupled to antirabbit antibody (DAKO En-
Vision + System HRP; DAKO), developed with diaminoben-
zidine for 10 minutes and counterstained with hematoxylin.
For Epo and EpoR immunohistochemistry, slides of fetal
liver and placenta were used as positive controls. The speci-
ficity of the Epo and EpoR antibodies was confirmed pre-
viously [2]. In addition, the specificity of the EpoR and Epo
immunoreactivity was also evaluated by the antibody ab-
sorption test: the primary antibody was preincubated with
blocking peptide for EpoR (Santa Cruz Biotechnologies) or
human recombinant Epo (rHuEpo; R&D Systems, Minne-
apolis, MN) (10:1 peptide/antibody ratio), which resulted
in complete abolishment of immunohistochemical staining.
The specificity of the immunostaining reaction is further
supported by other experiments using a mouse monoclonal
anti-Epo (clone 9C21D11; R&D Systems) and a rabbit
polyclonal anti-EpoR antibody (Upstate Biotechnology, Inc.,
Lake Placid, NY) [3,8,9], which resulted in an immunostain-
ing pattern similar to that obtained with antibodies used in the
current study. For cell line staining, cells were fixed with 10%
formalin and stained for Epo as described above.
Interpretation of Immunohistochemical Stains
Immunohistochemical stains for Epo and EpoR were
interpreted semiquantitatively by assessing the intensity
and extent of staining on the entire tissue sections present
on the slidesaccording toa four-tiered (0–3) scale [3]. ForEpo,
cytoplasmic—for EpoR, cytoplasmic and/or membrane—
immunoreactivity was considered positive. In the case of
dysplasias or in situ carcinomas, first, the percentage of total
epithelial thickness showing positive staining was determined
(e.g., 50% if the basal half or 75% if the basal three-fourths
of the squamous epithelium showed positive immunostain-
ing, etc.). In the case of invasive tumors, first, the total per-
centage of positively staining tumor cells was determined.
Then the percentage of: 1) weakly, 2) moderately, and 3)
strongly staining cells was determined, so that the sum of
these categories equated with the overall percentage of
positivity. A staining score was then calculated as follows:
Score (out of maximum of 300) = S of 1  percentage of
weak, 2  percentage of moderate, and 3  percentage of
strong staining.
Statistical Analysis
The Wilcoxon signed rank test was used for the compar-
ison of median EpoR and Epo immunohistochemical expres-
sion levels in invasive squamous cell carcinoma, squamous
cell dysplasia, and adjacent benign squamous epithelium.
Median EpoR and Epo immunohistochemical expression
levels in benign epithelia, dysplasia, and invasive carcinoma
were compared using the Kruskal-Wallis one-way analysis of
variance by ranks followed by Dunn’s multiple comparison
test, when appropriate. Statistical significance was estab-
lished if the two-sided P value of a test was less than .05.
Cell Culture and Hypoxia Treatments
Human JHU-O22SCC (from here on referred to as 022)
and UM-SCC-22B (from here on referred to as 22B) cancer
cells were cultured in RPMI 1640 (Sigma, St. Louis, MO)
supplemented with 10% fetal bovine serum (FBS) and
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand
Island, NY) containing a high amount of glucose (25 mM)
with 10% FBS, respectively. Hep3B and DU145 cells ob-
tained from the ATCC (Manassas, VA) were cultured with
high-glucose DMEM and RPMI 1640, respectively. All media
were supplemented with 1% (vol/vol) penicillin/streptomycin.
Cell lines were maintained in 21% O2, 5% CO2, and 74% N2
in a humidified cell incubator at 37jC. For hypoxia treat-
ments, culture dishes were sealed in a humidified chamber
and flushed with a gas mixture of 1% O2, 5% CO2, and 94%
N2, and incubated at 37jC for the time indicated.
Western blot analysis and Immunoprecipitations
For cell extract preparation, cell pellets from 100% con-
fluent 10-cm culture dishes were lysed in RIPA buffer [0.1%
sodium dodecyl sulfate (SDS), 1% NP-40, 5 mM EDTA,
0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris–
HCl, with 2 mM DTT and protease inhibitors cocktail] for
60 minutes on ice. Lysates were centrifuged (4jC) at
16,000g for 10 minutes and the supernatant was collected
for Western blot analysis. For hypoxia-inducible factor 1
(HIF-1) a and EpoRWestern blot analysis, whole cell lysates
were resolved using 4% to 12% polyacrylamide SDS gel
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(100 mg for HIF-1a and 50 mg for EpoR). Proteins were
transferred to nitrocellulose membrane, blocked with 5%
nonfat dry milk in TBS-T (50 mM Tris, pH 7.6, 150 mM NaCl,
and 0.1% Tween-20), and probed with HIF-1a monoclonal
antibody 1:350 (Transduction Laboratories, San Diego, CA)
and EpoR rabbit polyclonal antibodies (C20) 1:1500 (Santa
Cruz Biotechnologies) overnight at 4jC as previously de-
scribed by us [2,3,8]. Horseradish peroxidase–conjugated
secondary antibodies were used to probe membranes:
sheep antimouse (Amersham Pharmacia Biotech, Piscat-
away, NJ) for HIF-1a 1:2000 and goat antirabbit for EpoR
(1:5000). Immunoreactive bands were visualized using
chemiluminescence (SuperSignal WestPico Chemilumines-
cence kit; Pierce, Rockford, IL). Phospho-Janus kinase 2
(p-JAK2) immunoprecipitations were performed as pre-
viously described [12]. Briefly, cells were lysed and immuno-
precipitations were performed with 5 g of JAK2 antibody
(Upstate Biotechnology, Inc.) and protein A-Sepharose
beads (Boehringer Mannheim, Indianapolis, IN). Immuno-
precipitates were separated on 8.75% polyacrylamide SDS
gel, transferred to nitrocellulose membrane, and probed with
a monoclonal antiphosphotyrosine 4G10 antibody 1:1000
(Upstate Biotechnology, Inc.). HIF-1 and EpoR Western blot
protein levels were quantified using densitometry. Immuno-
reactive bands were captured on high-performance chemilu-
minescence film (Amersham Biosciences, Pascataway, NJ)
and scanned. Densitometry of bands was quantified with
ImageJ (http://rsb.info.nih.gov/ij/). Equal protein loading
was determined by BioRad (Hercules, CA) protein assay
and independently verified by b-actin immunoreactivity.
Three independent experiments were performed for each
protein, results were graphed, and a two-tailed Student’s
t test was performed to determine significance. P values
less than .05 were considered significant.
Reverse Transcription Polymerase Chain Reaction
(RT-PCR) and Quantitative RT-PCR Analysis for Epo
Gene Expression
Total RNA from cells was isolated using the RNeasy Mini
Kit (Qiagen, Inc., Valencia, CA). cDNA was generated from
5 mg of total RNA using iScript cDNA Synthesis Kit (BioRad).
PCR was conducted using MAXIscript SP6 (Ambion, Austin,
TX) with 1 ml of cDNA template and 0.3 mM of forward and
reverse primers. The primers for Epo were: forward (5V-
TCACTGTCCCAGACACCAAA-3V) and reverse (5V-GGG-
AAGAGTTGACCAACAGG-3V), which correspond to base
pairs 378 to 518. PCR cycling conditions were 40 cycles
at 94jC for 30 seconds, 60jC for 30 seconds, and 72jC for
60 seconds. PCR products were run on a 4% agarose gel
along with a 50-bp ladder (Invitrogen, Corp., Carlsbad, CA)
Primers for control gene HPRT were: forward (5V-TGA-
CACTGGCAAAACAATGCA-3V) and reverse (5V-GGTCC-
TTTTCACCAGCAAGCT-3V). For quantitative real-time
PCR analysis, the SYBR Green PCR Master Mix (Perkin
Elmer, Boston, MA) and the BioRad Detection System
were used. Single-band amplification was verified through
multicomponent analysis. Primers for EPOR were: forward
(5V-GGCAGTGTGGACATAGTGGC-3V) and reverse (25V-
AGCAGGATGGATTGGGCAGA-3V); primers for GLUT3
were: forward (5V-TGACGATACCGGAGCCAATG-3V) and
reverse (5V-TCAAAGGACTTGCCCAGTTT-3V). Primers for
control gene GUS were: forward (5V-GAAAATATGTGGTT-
GGAGAGCTCATT-3V) and reverse (5V-CCGAGTGAAGAT-
CCCCTTTTTA-3V).
Cell Invasion Assay
Cell invasion experiments were performed using 24-well
Biocoat Matrigel Invasion Chambers with an 8-mm pore
polycarbonate filter according to the manufacturer’s instruc-
tions (cat no. 35-4480; Becton Dickinson Labware, Bedford,
MA). Growth factor– reduced Biocoat Matrigel Invasion
Inserts were used for Hep3B cells and DU145 cells (Epo
invasion–enhancing dose 200 U/ml). Prior to experimenta-
tion, all invasion chamber inserts were hydrated according
to the manufacturer’s protocol. Briefly, cells in the growing
phase were trypsinized and resuspended at a concentra-
tion of 2  105 cells/ml in media with 0.5% FBS. The lower
compartment of the plates received 750ml of serum-free
media. All drug treatments were added to the lower com-
partment of the plate prior to cell plating. An amount of 1 
105 cells was plated in each insert and allowed to invade for
48 hours at 37jC in a humidified incubator with 21% O2.
Cells that remained inside the insert after 48 hours were
thoroughly wiped with a cotton swab and invading cells were
fixed and stained using Diff-Quick Stain Solution (Dade
Behring, Newark, DE). Images of invading cells were cap-
tured and quantified by counting the number of stained cells
in five predetermined fields at 20 magnification (the aver-
age number of cells per field for O22 cells and 22B cells
under serum-free conditions was 5 and 61, respectively). All
treatments groups were performed with an n of six inserts.
The difference in invasion between treatment groups was
statistically analyzed using a two-tailed Student’s t test.
Recombinant Epo was purchased from AMGEN (Thousand
Oaks, CA). AG490 was from Sigma.
Results
To investigate whether Epo signaling might play a direct role
in HNSCC progression, we examined the immunohisto-
chemical expression of Epo and EpoR proteins in biopsy
samples obtained from oral cavity, oropharyngeal, hypo-
pharyngeal, and laryngeal lesions of patients not previously
treated with rhEpo. Our analysis revealed high levels of
both Epo and EpoR expression in the carcinomas examined
(25/32 and 32/32, respectively). In normal tissues, EpoR
staining was low and confined to the basal epithelial layer
(Figure 1a). Strong EpoR staining was seen throughout the
dysplastic epithelium, in invasive carcinoma cells, and in
lymph node metastases. Tumoral vascular elements also
showed prominent EpoR immunoreactivity. Epo staining of
normal elements was undetectable in most samples
(Figure 1a). Within tumors, however, Epo immunoreactivity
was typically seen in the perinecrotic rims, which are known
to be severely hypoxic [13]. Discretely intense Epo staining
was also seen in invasive carcinoma cells, but was not
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as uniformly expressed as EpoR staining. A statistically
significant correlation between tumor progression and
immunohistochemical staining for EpoR (Figure 1b) and
Epo (Figure 1c) was demonstrated.
We next explored the biologic regulation and actions of
Epo signaling in cancer cells using human HNSCC cell lines.
The 022 and the 22B HNSCC cell lines were specifically
chosen because they are known to differ significantly in their
basal expression levels of the oxygen-responsive HIF-1a
subunit of HIF-1 as well as in their relative invasiveness
through Matrigel [14]. Expression of EpoR mRNA was de-
tected by RT-PCR in both cell lines (Figure 2a). However,
despite the basal expression of Epo mRNA and immuno-
reactivity (Figure 2, b and c), neither cell lines displayed an
upregulation of Epo expression on treatment with hypoxia
(1% O2) for 24 hours (Figure 2, d and e). Epogene expres-
sion is regulated by the HIF-1 [15]. However, the absence of
hypoxic Epo regulation was not due to a lack of hypoxic
responsiveness as demonstrated by hypoxic induction of
the HIF-1–regulated glucose transporter geneGlut-3 in both
cell lines (Figure 2, d and e). Moreover, hypoxia clearly in-
duced nuclear accumulation of the oxygen-regulated HIF-1a
protein in both cell lines and also upregulated EpoR protein
expression (Figure 2, f–h) as reported previously for other
human cancers [2,3].
The 22B cells also display greater invasiveness through
Matrigel-coated Boyden chambers than the 022 cells [14]
(Figure 3a). To find out whether Epo signaling could influ-
ence the invasive behavior of HNSCC cells, we treated both
cell lines with increasing doses of rhEpo (in the form of
Epoetin-a). Remarkably, Epoetin-a promoted invasiveness
in both cell lines (Figure 3b). The O22 cells displayed a
greater response to Epo when expressed as percent
change, although this may have been due to the much higher
basal invasiveness seen in the 22B cells. A bell-shaped
dose–response relationship was observed for Epo-induced
invasiveness and similar responses have been previously
reported for other cellular actions of Epo [16]. Epoetin-a
(200 U/ml) also prominently induced invasiveness in the
human hepatoma cell line, Hep3B, and the human prostate
cancer cell line, DU145 (Figure 3c). Both of these cancer cell
types have been shown to express EpoR and have specifi-
cally been proposed as useful experimental models for
studying the potential for growth regulation by Epo–EpoR
in an autocrine or paracrine manner [17,18]. We next exam-
ined the involvement of EpoR signaling in mediating Epoetin-
a–induced invasiveness in HNSCC cells. On binding Epo,
dimerization of EpoR recruits and activates the JAK2 tyro-
sine kinase, which then phosphorylates itself along with other
signaling components [19]. As shown in Figure 3d, Epoetin-a
promoted tyrosine phosphorylation of JAK2 in both 022 and
22B cells. Moreover, Epoetin-a stimulation of JAK2 phos-
phorylation was blocked by the specific JAK2 inhibitor,
AG490 [20]. Epoetin-a–induced HNSCC cell invasion was
also blocked by AG490, thus implicating the involvement of
the EpoR–JAK2 signaling pathway in this effect (Figure 3e).
Moreover, the high basal invasiveness of 22B cells was
also blunted by AG490 (Figure 3f ), suggesting that an
Figure 1. EpoR and Epo immunohistochemistry in HNSCC. (a) Top row: A prominent increase in EpoR staining (brown color) is seen in biopsies with dysplastic
(left panel) and invasive carcinoma cells (middle panel) as well as in tumoral vasculature (right panel). Middle row: EpoR immunoreactivity in normal epithelium
(left panel), dysplasic epithelium (middle panel), and invasive carcinoma (right panel). Bottom row: Epo immunoreactivity in normal epithelium (left panel),
perinecrotic tumor region (middle panel), and invasive carcinoma (right panel). (b) EpoR and Epo expression in lymph node metastasis. EpoR staining is seen in
metastatic cancer cells (M) but not in normal lymphocytes (L). Epo staining is most prominent in the malignant cells bordering necrotic regions (N). (c) Correlation
of EpoR and Epo immunoreactivity with malignant progression. P values of EpoR staining were calculated for benign and dysplasia (**P < .01), benign and
carcinoma (***P < .001), and dysplasia and carcinoma ( P > .05). P values of Epo staining were calculated for benign and dysplasia (***P < .001), benign and
carcinoma (***P < .001), and dysplasia and carcinoma (*P < .05). Bars indicate median immunostaining score values. NS = not significant.
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autocrine Epo signaling mechanism may play a role in the
invasion of some HNSCC.
Discussion
We have shown that Epo signaling elements are prominently
expressed in head and neck cancers. Other studies have
recently identified biologically active Epo signaling in human
breast and uterine cancers and have correlated the expres-
sion of Epo and EpoR with poor prognosis [3,8,9]. The
correlation we report here between Epo and EpoR expres-
sion and malignant progression in head and neck cancer
is consistent with these previous observations. Although it
is possible that some of the Epo immunostainings associ-
ated with cancer cells may be accumulated from peripheral
sources, the detection of Epo mRNA and protein in cultured
HNSCC cell lines demonstrates that this hormone can be
ectopically produced in this type of cancer. The mechanism
underlying Epo and EpoR gene expression in cancer cells
is not entirely clear. EpoR, but not Epo, expression was
observed in the basal cell layer of normal oral mucosa
(Figure 1a). Such expression patterns, which were also seen
previously in cervical squamous epithelium [3], suggest that
the recently recognized role for Epo signaling in gut epithe-
lium development [27] may also extend to other epithelia.
Expression of both Epo and EpoR can be stimulated by
hypoxia [21,22], and the HNSCC cell lines we examined
displayed hypoxia-inducible upregulation of EpoR expres-
sion rather than Epo. The higher normoxic expression of
EpoR in the 22B cell line is correlated with their higher basal
HIF-1a expression and invasiveness [14]. HIF-1a is the
key regulatory subunit of HIF-1, a transcription factor that
Figure 2. Differential invasiveness of HNSCC cell lines correlates with higher HIF and EpoR expression. (a) Quantitative real-time PCR analysis of EpoR from O22
and 22B cell cDNA with HPRT as control gene. (b) PCR amplification of Epo from O22 and 22B cell cDNA with HPRT as control gene. (c) Epo immunocytochemistry
demonstrated protein expression in normoxic O22 cells and 22B cells, Epo antibody concentration 1:200, and no primary control exhibited no staining.
(d) Quantitative real-time PCR analysis of Epo and GLUT3 mRNA levels in O22 cells after 24 hours of treatment with hypoxia. The amount of each mRNA in samples
was normalized to the average of HPRT1 mRNA and GUS mRNA in the same sample. (e) Quantitative real-time PCR analysis of Epo and GLUT3 mRNA levels in
22B cells cultured for 24 hours under hypoxia. The amount of each mRNA in samples was normalized to the average of HPRT1 mRNA and GUS mRNA in the same
sample. (f) Differential expression of HIF-1 and EpoR expression in 022 and 22B HNSCC cells. For hypoxia treatment, cells were exposed to 1% O2 for 24 hours.
(g) HIF-1 protein levels from (f) were quantified using densitometry. Densitometry values from three independent experiments were graphed and a two-tailed
Student’s t test was performed to compare relative HIF-1 levels of indicated treatment groups. (*, **, ***P < .05; all treatment groups were compared to HIF-1 levels of
normoxic O22 cells). (h) EpoR protein levels from (f) were quantified using densitometry. Densitometry values from three independent experiments were graphed
and a two-tailed Student’s t test was performed to compare EpoR levels of normoxia- versus hypoxia-treated cells (*P < .05).
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controls the gene expression of Epo and other hypoxia-
responsive genes. High basal and hypoxia-inducible HIF-1
expression is observed in solid tumors [23] and has been
linked to increased angiogenesis [24], enhanced invasive-
ness [14,24,25], and poor clinical outcome [26]. It is possible
that some of the adverse effects correlated with HIF-1 ex-
pression in cancer are mediated by Epo signaling.
Although hypoxia did not induce Epo mRNA expression in
either cell line, RT-PCR experiments and immunocyto-
chemical detection of Epo protein support an active consti-
tutive production of the cytokine. Epo is known to exhibit
tissue-restricted expression with hypoxia and several known
growth factors can modulate its expression levels [27]. The
mechanisms regulating the normoxic expression of Epo in
these cells are unknown. Methylation of the CpG sites in
the Epo promoter interferes with HIF-1 binding, which ulti-
mately restricts Epo gene expression under hypoxia [28].
Fetal liver, uterine epithelium, and embryonal carcinoma
cells can express Epo in a hypoxia-independent fashion
through the action of GATA 4 [29], steroid receptor [30],
and retinoic acid receptor [31] transcription factors, respec-
tively. It is possible that one or more of these mechanisms
contribute to constitutive Epo expression in HNSCC cell
lines. The association of Epo staining with perinecrotic
hypoxic regions in head and neck tumor biopsies also
suggests that HIF-1 may regulate Epo expression in many
such cancers. Although the ability of Epo to promote angio-
genesis and improve cell survival has been suggested to
play a role in human cancer, our report is the first to
demonstrate an effect of Epo on cancer cell invasiveness.
Exogenous Epo activated JAK2 phosphorylation and stimu-
lated cell invasion of both HNSCC cell lines, whereas a
JAK2 inhibitor blocked this effect. JAK2 can activate
several intracellular signaling cascades including the phos-
phorylation of the STAT family of transcription factors [19].
STATs have been implicated in tumorigenesis [32] pre-
viously but have yet to be examined for a role in invasive-
ness. Activation of the JAK–STAT signaling pathway by Epo
is well appreciated in erythroid precursors and endothelial
cells. Epo is known to induce an invasive, pro-angiogenic
phenotype in endothelial cells as well as neovascularization
in vivo [33]. These processes correlate with Epo-induced
JAK2 phosphorylation and matrix metalloprotease-2 produc-
tion in endothelial cells [33,34]. Moreover, rhEpo can pro-
mote migration of enterocytes [35], in addition to stimulating
the migration of burst-forming unit erythroids (BFU-E) from
the bone marrow to the spleen [36]. The ability of Epo
signaling to increase the migratory or invasive behavior of
cells may thus be a widespread but underappreciated activity
important for normal development and physiology [37,38]. As
suggested by our demonstration of Epoetin-a–induced in-
vasion of hepatoma and prostate cancer cells, constitutive or
hypoxia-inducible expression of this activity may contribute
to the invasiveness of several different human cancers.
Biologic actions of Epo signaling in cancer cells are just
beginning to be appreciated. The adverse clinical outcome in
rhEpo-treated patients recently reported in two clinical trials
has heightened the importance of understanding Epo effects
on cancer cells. Although our data do not completely explain
the findings of these trials, our demonstration of functional
EpoR expression and Epoetin-a–induced biologic effects on
HNSCC cells does show that rhEpo can directly impact head
and neck cancer. We propose that autocrine or paracrine
Epo signaling can enhance cancer invasion and that the
indiscriminate treatment of cancer patients with rhEpo
should be re-examined.
Figure 3. Epo signaling mediates invasion in HNSCC cell lines. (a) 22B cells display higher invasive potential as assayed with Matrigel coated Boyden chambers
for a 48-hour period under serum-free conditions (*P < .05). (b) Exogenous rhEpo promotes cell invasion of O22 and 22B cells through Matrigel-coated Boyden
chambers under serum-free conditions (48 hours; *P < .05). (c) Exogenous rhEpo promotes cell invasion of hepatoma (Hep3B) and prostate (DU145) cancer cell
lines through Matrigel-coated Boyden chambers under serum-free conditions (48 hours; *P < .05). (d) Exogenous rhEpo (10 U/ml) treatment enhances
phosphorylation of JAK2 and this activation is blocked with AG490 (20 M; *P < .05). (e) Epo (10 U/ml) – induced invasion in O22 cells is blocked with AG490
(20 M) treatment (*P < .05). (f) Basal invasion of 22B cells is reduced with AG490 (20 M) treatment only under serum-free conditions (*P < .05).
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